AMENDMENTS TO THE CLAIMS

The following is a complete list of the pending claims.

1-8. (Cancelled)

9. (Currently amended) A diagnostic kit comprising a phospho-peptide wherein the phospho-peptide ~~is between~~ consists of 15 to 60 ~~and 100~~ amino acids in length, wherein the phospho-peptide is liable to form an immunological complex with monoclonal antibody HT7 and monoclonal antibody AT270, and wherein the phospho-peptide comprises:

(a) the minimal epitope of HT7: ProProGlyGlnLys (SEQ ID NO:1 [[NO 1]]); and

(b) the minimal epitope of AT270: ProProAlaProLysThr(p)Pro (SEQ ID NO:2 [[NO 2]]).

10. (Currently amended) The diagnostic kit of claim 9 wherein the phospho-peptide comprises the sequence: ProArgGlyAlaAlaProProGlyGlnLysGlyGlnAlaAsnAlaThrArgIleProAlaLysThrPro ProAlaProLysThr(p)ProProSerSerGlyGlu (SEQ ID NO:3 [[NO 3]]) or a variant sequence ~~sequences~~ thereof, wherein said variant sequence comprises SEQ ID NO:1 or SEQ ID NO:2 ~~on the condition that they still bind to the HT7 and the AT270 monoclonal antibodies~~.

11. (Original) The diagnostic kit of claim 9 wherein the phospho-peptide comprises the sequence of SEQ ID NO:3.

12. (Original) The diagnostic kit of claim 9 wherein the phospho-peptide consists of the sequence of SEQ ID NO:3.

13. (Currently amended) The diagnostic kit of claim 9 wherein the phospho-peptide consists of ~~is from~~ 20 to 50 amino acid residues in length.

14. (Currently amended) The diagnostic kit of claim 9 wherein the phospho-peptide consists of ~~is from~~ 30 to 40 amino acid residues in length.

15. (Currently amended) A phospho-peptide comprising:

(a) the minimal epitope of HT7: ProProGlyGlnLys (SEQ ID NO:1 [[NO 1]]); and

(b) the minimal epitope of AT270: ProProAlaProLysThr(p)Pro (SEQ ID NO:2 [[NO 2]]);

wherein the phospho-peptide ~~is between~~ consists of 15 to 60 ~~and 100~~ amino acids in length and wherein the phospho-peptide is liable to form an immunological complex with monoclonal antibody HT7 and monoclonal antibody AT270.

16. (Currently amended) The phospho-peptide of claim 15 that comprises the sequence ProArgGlyAlaAlaProProGlyGlnLysGlyGlnAlaAsnAlaThrArgIleProAlaLysThrProProAla ProLysThr(p)ProProSerSerGlyGlu (SEQ ID NO:3 [[NO 3]]) or a variant sequence ~~sequences~~ thereof, wherein said variant sequence comprises SEQ ID NO:1 or SEQ ID NO:2 ~~on the condition that they still bind to the HT7 and the AT270 monoclonal antibodies~~.

17. (Original) The phospho-peptide of claim 15 comprising the sequence of SEQ ID NO:3.

18. (Original) The phospho-peptide of claim 15 consisting of the sequence of SEQ ID NO:3.

19. (Currently amended) The phospho-peptide of claim 15 that ~~is from~~ consists of 20 to 50 amino acid residues in length.

20. (Currently amended) The phospho-peptide of claim 15 that ~~is from~~ consists of 30 to 40 amino acid residues in length.

21. (Currently amended) A method for measuring the level of phospho-tau (181) in a sample comprising:

(a) detecting phospho-tau (181) in a sample immunologically, thereby obtaining an experimental result, and quantifying the experimental result; and

(b) providing ~~using~~ a phospho-peptide described in any one of [[the]] claims 15 through 20 as a standard for determining ~~to determine~~ the level of phospho-tau (181) in the sample of step (a) by:

(1) detecting said phospho-peptide in one or more control samples immunologically as in (a), wherein the amount or concentration of said phospho-peptide in said control samples is known, thereby obtaining control results; [[.]]

(2) quantifying the ~~experimental~~ control results; ~~result observed in step (1);~~

~~(3) comparing the experimental result observed from detecting phospho-tau in step (a) to the results obtained in step (1);~~ and

(3) [[(4)]] correlating the quantified experimental result with the quantified control results and known control amounts or concentrations to calculate ~~calculating~~ the level of phospho-tau (181) in the sample of step (a) ~~based on the information obtained from steps (2) and (3)~~.